Platelet-rich plasma effect in infertility

Phase 2

• Conditions: Diseases of the genitourinary system.; Female infertility; Complications associated with artificial fertilization; N97; N98

• Registration Number: IRCT20160815029374N7
• Lead Sponsor: Sari University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 26 August 2019

Recruitment & Eligibility

• Status: Complete
• Sex: Female
• Target Recruitment: 10

Inclusion Criteria

Diminished ovarian reserve
At least one prior failed in vitro fertilization
Body mass index lower than 30 Kilogram per square meter
Premature ovarian failure

Exclusion Criteria

Hematologic disorders (blood cancer, thrombocytopenia)
Immunologic disorders (anti-phospholipid syndrome, thrombophilia)
Hormonal disorders (diabetes, thyroid, hyperprolactinemia)
Chromosomal anomalies and genetics (herditary or congenital)
Renal failure

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in Anti mulerian hormone level. Timepoint: Two weeks after oocyte pick up compared with two week before injection of of Calcium Gluconate-activated platelet-rich plasma (the day of pick up oocyte). Method of measurement: Assaying this factor in blood serum is done by laboratory methods and the corresponding kit.;Changes in the level of follicular stimulating hormone. Timepoint: Two weeks after oocyte pick up compared with two week before injection of of Calcium Gluconate-activated platelet-rich plasma (the day of pick up oocyte). Method of measurement: Assaying this factor in blood serum is done by laboratory methods and the corresponding kit.;Change in estradiol level. Timepoint: Two weeks after oocyte pick up compared with two week before injection of of Calcium Gluconate-activated platelet-rich plasma (the day of pick up oocyte). Method of measurement: Assaying this factor in blood serum is done by laboratory methods and the corresponding kit.

Secondary Outcome Measures

Name	Time	Method
Change in Antral fulicular counts. Timepoint: The third day of menstruation and before B-HCG injection. Method of measurement: by ultrasound and folliculography.;Change in oocyte numbers. Timepoint: Two months after Calcium Gluconate- activated platelet-rich plasma injection comparison with the day of Oocyte pick up. Method of measurement: evaluation by microscope and ultrasound.;Pregnancy rate. Timepoint: Three monthes after Calcium Gluconate - activated platelet-rich plasma injection then survey chemical and clinical pregnancy. Method of measurement: Positive beta hCG rate and clinical pregnancy rates.;Change in embryos numbers. Timepoint: Two months after intraovarian injection of platelet. Method of measurement: by counting frozen embryo in embryo bank.